NCCN 2017 Congress Webinar Series™: Lung Cancer - What, When, and How of Biomarker Testing in Non-Small Cell Lung Cancer

October 9, 2017

The goal of this educational program is to ensure that members of a multidisciplinary team, including physicians, nurses, pharmacists, and other relevant healthcare professionals, have the knowledge and skills necessary to apply the standards of care to their practices and healthcare settings for patients with lung cancer and those being screened for lung cancer.

Target Audience

This educational program is designed to meet the educational needs of oncologists, pathologists, nurses, pharmacists, and other health care professionals who manage patients with lung cancer and those being screened for lung cancer.

Additional information
Supporters: 

This activity is supported by educational grants from AstraZeneca; Celgene Corporation; Genentech; Lilly; Novartis; Pfizer; and Takeda Oncology. This activity is supported by independent educational grants from AbbVie and Boehringer Ingelheim Pharmaceuticals, Inc.

Course summary
Available credit: 
  • 0.75 ACPE contact hours
  • 0.75 ANCC contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 Participation
Course opens: 
08/01/2017
Course expires: 
12/03/2017
Event starts: 
10/09/2017 - 4:00pm
Event ends: 
10/09/2017 - 4:45pm
Cost:
$0.00

Matthew A. Gubens, MD, MS
UCSF Helen Diller Family Comprehensive Cancer Center

Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.

Definitions

The ACCME/ANCC/ACPE defines “conflict of interest” as when an individual has an opportunity to affect CE content about products or services of a commercial interest with which he/she has a financial relationship.

ACCME, ACPE, and ANCC focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CE activity. ACCME, ACPE, and ANCC have not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME, ACPE, and ANCC defines “relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.

Faculty Disclosures

The faculty listed below disclose the following relevant financial relationships:
Matthew A. Gubens, MD, MS
AbbVie: Consulting Fees, Honoraria
ARIAD Pharmaceuticals, Inc.: Consulting Fees, Honoraria
AstraZeneca Pharmaceuticals LP: Consulting Fees, Honoraria
Bristol-Myers Squibb Company: Consulting Fees, Honoraria
Celgene Corporation: Grant/Research Support
Genentech, Inc.: Consulting Fees, Honoraria
Merck & Co., Inc. Grant/Research Support
Mersana Therapeutics, Inc.: Consulting Fees, Honoraria
Novartis Pharmaceuticals Corporation: Grant/Research Support
Novartis Pharmaceuticals Corporation: Consulting Fees, Honoraria
OncoMed Pharmaceuticals: Grant/Research Support
Roche Laboratories, Inc.: Grant/Research Support

The NCCN Activity Planning staff listed below disclose no relevant financial relationships:
Kim Bayer; Mark Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Joan S. McClure, MS; Diane McPherson; Melanie Moletzsky; Lisa Perfidio; Liz Rieder; Shannon K. Ryan; Kathy Smith; Melinda Somasekhar, PhD

The NCCN Clinical Information staff listed below, who has reviewed content, disclose no relevant financial relationships:
Miranda Hughes, PhD; Alyse Johnson-Chilla; Rashmi Kumar, PhD

Faculty Disclaimers

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation to the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.

Physicians
National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NCCN designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 0.75 hours of Category I credit for completing this activity.

Nurses
National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

NCCN designates this educational activity for a maximum of 0.75 contact hours.

Pharmacists

National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

NCCN designates this knowledge-based continuing education activity for 0.75 contact hours (0.075 CEUs) of continuing education credit. UAN to be determined.

Available Credit

  • 0.75 ACPE contact hours
  • 0.75 ANCC contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 Participation

Learning Objectives

Following this activity, participants should be able to:

  • Identify the appropriate use of liquid biopsy and tissue biopsy in assessing for biomarkers in patients with metastatic NSCLC.
  • Describe the recommended molecular testing for patients with NSCLC and sensitizing EGFR mutations and T790M.
  • Summarize the currently known mechanisms for primary and secondary resistance to erlotinib, gefitinib, and afatinib.

Accreditation Period

Course opens: 
08/01/2017
Course expires: 
12/03/2017

Price

Cost:
$0.00
Please login or register to take this course.

Click the Take Course button to register for this live webinar.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing